Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease

Mar 27, 2017 17:00 JST

Source: Proteomics International Laboratories Ltd (PILL)

SHANGHAI, Mar 27, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month. PILL managing director Dr Richard Lipscombe is in Shanghai this week meeting with possible commercialisation partners for China, and is showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.

Managing Director Dr Richard Lipscombe in the PILL Laboratories at Harry Perkins Institute of Medical Research in Perth, Western Australia.

Dr Lipscombe said the new report, titled Biomarkers Enabling Diabetes and Obesity Management, identifies PromarkerD as the world leader. The report says novel biomarker research is likely to transform the future of obesity and diabetes management.

Frost & Sullivan states that novel tools like PromarkerD can allow enhanced management of obesity, diabetes and related complications in the near future, and goes on to highlight PILL's novel test for diabetic kidney disease noting its high adoption potential.[1]

PromarkerD technology has also been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).[2]

There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.

PILL already has a deal in place with Chinese biopharmaceutical company Newsummit Biopharma Co. (NSB) to manufacture the PromarkerD kit in China. The process includes engagement of Key Opinion Leaders and Hospitals, who will facilitate validation of the completed kit.

Publication details
[1] 'Biomarkers Enabling Diabetes and Obesity Management' published by Frost & Sullivan, March 2, 2017. For the report, http://bit.ly/2nqMfNY.
[2] 'Comprehensive Mass Spectrometry Based Biomarker Discovery and Validation Platform as Applied to Diabetic Kidney Disease' published in EuPA Open Proteomics, the official journal of the European Proteomics Association, March 1, 2017. http://bit.ly/2nqMfNY for the research paper.

Multimedia
Presentation: An audio summary of the research paper. http://bit.ly/2nqMfNY
Video: The power of the Promarker platform for personalised medicine. http://bit.ly/2nqMfNY

PromarkerD - a predictive diagnostic test for diabetic kidney disease --
The EuPA journal article followed evaluation by independent scientific experts and serves to verify the process used to develop and test PILL's PromarkerD protein 'fingerprint? that measures kidney disease in patients with diabetes. This novel test can both diagnose and predict disease.

In diabetic patients already suffering from chronic kidney disease PromarkerD could diagnose the presence of disease that was missed by the current gold standard tests (known as the ACR and eGFR tests).

Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In an extension of the published work 576 patients were followed in a four-year longitudinal clinical study. PromarkerD correctly predicted 95% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.

About the Promarker Platform --
PILL's diagnostic research is made possible by the company's proprietary biomarker discovery platform termed Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.

The technology is so versatile it can be used to identify fingerprints from any biological source. The Promarker platform is also being applied to the asbestos-related cancer mesothelioma, the gastro-causing parasite Giardia (in partnership with a US veterinary company) and endometriosis, a condition that affects one in ten women in their reproductive years.

About Proteomics International Laboratories (PILL) --
PILL (ASX: PIQ) is a medical technology company focused on proteomics - the industrial scale study of the structure and function of proteins. As proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems, proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.

PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.

The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:

1. Diagnostics: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease.
By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion.
2. Analytical services: Specialist contract research fee-for-service model - focus on biosimilars QC.
The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent.
3. Drug discovery: Therapeutic peptide drug discovery - focus on painkillers and antibiotics.
The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase by over 10% per year during 2016-2025.

For further information, please visit www.proteomics.com.au, or contact:

Dr Richard Lipscombe
Managing Director,
Proteomics International Laboratories Ltd
E: enquiries@proteomics.com.au
T: +61 2 8218 2144

Media Contact:
Susan Fitzpatrick-Napier
Digital Mantra Group
E: team@dmgpr.com
T: +61 8 9389 1992

Source: Proteomics International Laboratories Ltd (PILL)
Sectors: BioTech, Healthcare & Pharm